Latest Headlines

Latest Headlines

Italy's Genenta Science raises $11M for gene therapy program at TIGET

Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.

Billionaires plot Stallergenes merger, Cerenis set for IPO, Big Pharma-backed Opsona eyes IPO

In this week's EuroBiotech Report, an investment vehicle backed by the megarich family that founded Serono plans to merge Stallergenes with Greer to create a transatlantic allergy immunotherapy player that can go toe-to-toe with Circassia and Merck. Cerenis Therapeutics has big plans of its own. And more.

Opsona edges closer to an IPO decision as PhIIb trial gets underway

Big Pharma-backed Opsona Therapeutics has looked into its future and seen a possible IPO on the horizon. The Dublin, Ireland-based immunology drug developer made the pronouncement as its lead candidate graduated to the second part of an adaptive Phase II trial.

Cerenis files for IPO to resurrect clinical-phase cholesterol drug

Cerenis Therapeutics has filed the paperwork for an IPO in Europe as it looks to bounce back from the failure of a Phase II trial of its HDL-like drug.

Billionaire's fund pitches immunotherapy merger for Stallergenes

An investment fund backed by the megarich family that founded Serono has proposed merging Stallergenes and Greer. The fund is well placed to make such a deal happen: It has a 77.3% stake in Stallergenes and owns Greer outright.

Government attention yet to stop slide in U.K. pharma R&D investment

The United Kingdom government has made the life science industry a focal point of its turnaround strategy, but data that have dripped out over the past few months show companies are spending less and less on developing and manufacturing drugs in the state.

Ex-Elan execs target €325M IPO for life science fund

Former Elan CEO Kelly Martin and other people with links to the Irish drugmaker are aiming to raise up to €325 million ($364 million) in an IPO to bankroll their life science investment fund. The IPO on the Irish Stock Exchange could dwarf last year's listing by Circassia and become one of the biggest floats in European biotech history.

Woodford forms Imperial-heavy board, Prexton exits Serono's shadow, Chiesi bags stem cell nod

In this week's EuroBiotech Report, Woodford looks set to go all in on south east England's academic hotspots. The U.K. government is set to further bolster the credentials of the region by setting up an international dementia institute within 5 years and lending its support to a dementia R&D investment fund. Prexton Therapeutics grabbed a slice of the CNS funding that is available today, raising €8.7 million ($9.9 million) to take its Parkinson's disease candidate into the clinic. And more.

Wall Street endorses Cyberonics, Sorin $3B merger to become neuromodulation, cardiac surgery player

Neuromodulation company Cyberonics and cardiovascular device player Sorin in an all-stock deal that now values the combination at $3 billion.

Ex-Merck Serono team bags €8.7M for PhI Parkinson's program

Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.